{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T07:40:44Z","timestamp":1778398844364,"version":"3.51.4"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1007\/s12185-010-0576-y","type":"journal-article","created":{"date-parts":[[2010,4,30]],"date-time":"2010-04-30T03:08:10Z","timestamp":1272596890000},"page":"897-902","source":"Crossref","is-referenced-by-count":11,"title":["Imatinib dose escalation in two patients with chronic myeloid leukemia, with low trough imatinib plasma levels measured at various intervals from the beginning of therapy and with suboptimal treatment response, leads to the achievement of higher plasma levels and major molecular response"],"prefix":"10.1007","volume":"91","author":[{"given":"Edgar","family":"Faber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Friedeck\u00fd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate\u0159ina","family":"Mi\u010dov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Divok\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beata","family":"Katrincs\u00e1kov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0160\u00e1rka","family":"Ro\u017emanov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Jaro\u0161ov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karel","family":"Indr\u00e1k","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom\u00e1\u0161","family":"Adam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,5,1]]},"reference":[{"key":"576_CR1","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27:6041\u201351.","journal-title":"J Clin Oncol"},{"key":"576_CR2","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1002\/cncr.24418","volume":"115","author":"Y Alvarado","year":"2009","unstructured":"Alvarado Y, Kantarjian H, O\u2019Brien S, Faderl S, Borthakur G, Burger J, et al. Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer. 2009;115:3709\u201318.","journal-title":"Cancer"},{"key":"576_CR3","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","volume":"112","author":"D Marin","year":"2008","unstructured":"Marin D, Milojkovic D, Olavarria E, Khorashad JS, de Lavallade H, Reid AG, et al. European LeukemiaNet criteria for failure or sub-optimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood. 2008;112:4437\u201344.","journal-title":"Blood"},{"key":"576_CR4","doi-asserted-by":"crossref","unstructured":"Larson RA, Druker BJ, Guilhot F, O\u2019Brien SG, Riviere GJ, Krahnke T, et al. for the IRIS (International Randomized Interferon vs. STI571) Study Group. Imatinib pharmacokinetics and its correlation with response and safety in chronic phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 2008;111:4022\u20138.","DOI":"10.1182\/blood-2007-10-116475"},{"key":"576_CR5","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","volume":"109","author":"S Picard","year":"2007","unstructured":"Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard M-A, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard dose imatinib in chronic myeloid leukemia. Blood. 2007;109:3496\u20139.","journal-title":"Blood"},{"key":"576_CR6","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00228-009-0621-z","volume":"65","author":"N Singh","year":"2009","unstructured":"Singh N, Kumar L, Meena R, Velpandian T. Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders. Eur J Clin Pharmacol. 2009;65:545\u20139.","journal-title":"Eur J Clin Pharmacol"},{"issue":"Suppl. 1","key":"576_CR7","first-page":"219","volume":"93","author":"E Faber","year":"2008","unstructured":"Faber E, Friedecky D, Tomkova J, Rozmanova S, Rohon P, Skoumalova I, et al. Imatinib plasma levels correlate with molecular response in CML patients. Haematologica. 2008;93(Suppl. 1):219\u201320 (Abstract 0543).","journal-title":"Haematologica"},{"key":"576_CR8","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","volume":"110","author":"DL White","year":"2007","unstructured":"White DL, Saunders VA, Dang P, Engler J, Venables A, Zrim S, et al. Most CML patients who have suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood. 2007;110:4064\u201372.","journal-title":"Blood"},{"key":"576_CR9","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.leukres.2008.07.015","volume":"33","author":"DL Forrest","year":"2009","unstructured":"Forrest DL, Trainor S, Brinkman RR, Barnett MJ, Hogge DE, Nevill TJ, et al. Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels. Leukemia Res. 2009;33:271\u20135.","journal-title":"Leukemia Res"},{"issue":"Suppl 2","key":"576_CR10","first-page":"259","volume":"94","author":"A Davies","year":"2009","unstructured":"Davies A, Hayes AK, Giannoudis A, Lucas CM, Knight K, Watmough SJ, et al. A study of plasma levels of imatinib and its bioactive metabolite CGP-74588 reveals no correlation with subsequent clinical outcome in imatinib-treated chronic myeloid leukemia. Haematologica. 2009;94(Suppl 2):259 (Abstract 0637).","journal-title":"Haematologica"},{"key":"576_CR11","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/leu.2009.88","volume":"23","author":"JE Cortes","year":"2009","unstructured":"Cortes JE, Egorin MJ, Guilhot F, Molimard M, Mahon F-X. Pharmacokinetic\/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia. Leukemia. 2009;23:1537\u201344.","journal-title":"Leukemia"},{"key":"576_CR12","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJM199403243301204","volume":"330","author":"The Italian Cooperative Study Group on chronic myeloid leukemia","year":"1994","unstructured":"The Italian Cooperative Study Group on chronic myeloid leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med. 1994;330:820\u20135.","journal-title":"N Engl J Med"},{"key":"576_CR13","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/0003-2697(87)90021-2","volume":"162","author":"P Chomczynski","year":"1987","unstructured":"Chomczynski P, Sacchi N. Single-step method of RNA isolation by quanidium thiocyanate\u2013phenol\u2013chloroform extraction. Anal Biochem. 1987;162:156\u20139.","journal-title":"Anal Biochem"},{"key":"576_CR14","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","volume":"17","author":"J Gabert","year":"2003","unstructured":"Gabert J, Beillard E, van der Velden VHJ, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of \u201creal-time\u201d quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia\u2014A Europe Against Cancer Program. Leukemia. 2003;17:2318\u201357.","journal-title":"Leukemia"},{"key":"576_CR15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1570-0232(03)00206-X","volume":"791","author":"RA Parise","year":"2003","unstructured":"Parise RA, Ramanathan RK, Hayes MJ, Egorin MJ. A sensitive high-performance liquid chromatography\u2013mass spectrometry assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma. J Chromatology B. 2003;791:39\u201344.","journal-title":"J Chromatology B"},{"key":"576_CR16","doi-asserted-by":"crossref","unstructured":"Osborn MP, White DL, Saunders VA, Cambareri B, Branford S, Menelaou A, et al. Early dose-escalation in chronic myeloid leukaemia patients with low plasma imatinib levels leads to equivalent BCR\u2013ABL values and drug levels at 6\u00a0months to those with optimal drug levels: first analysis from the TIDEL II trial of de-novo patients treated with 600\u00a0mg imatinib. Blood. 2009; 114(22):Abstract 1131.","DOI":"10.1182\/blood.V114.22.1131.1131"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-010-0576-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-010-0576-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-010-0576-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T05:15:30Z","timestamp":1591247730000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-010-0576-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,1]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["576"],"URL":"https:\/\/doi.org\/10.1007\/s12185-010-0576-y","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,1]]}}}